Good decision making requires good communication

Drug Safety

Volumn 35, Issue 11, 2012, Pages 983-993

  Fischhoff, Baruch ^a  

^a CARNEGIE MELLON UNIVERSITY   (United States)

Author keywords

Benefit risk assessment; Decision making; Regulatory process; Risk communication.

Indexed keywords

ACCURACY; ARTICLE; BENEFIT RISK FRAMEWORK; DECISION MAKING; HEALTH CARE POLICY; HUMAN; INTERPERSONAL COMMUNICATION; MEDICAL DECISION MAKING; PATIENT DECISION MAKING; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

COMMUNICATION; DECISION MAKING; DRUG TOXICITY; HUMANS; PHARMACEUTICAL PREPARATIONS; RISK ASSESSMENT; RISK FACTORS;

EID: 84867540720     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11636170-000000000-00000     Document Type: Article

References (58)

1. Mussen F, Salek S, Walker S. Benefit-risk appraisal of medicines: a systematic approach to decision making. Chichester: Wiley, 2009
2. Temple R. How FDA currently makes decisions on clinical trials. Clin Tri 2005; 2: 278-81
3. Woodcock J, Temple R, Midthun K, et al. FDA senior management perspectives (roundtable). Clin Tri 2005; 2: 383-8
4. Drummond MF, Shculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press, 2005
5. Gold MR, Siegel JE, Russell LB, et al., editors. Costeffectiveness analysis in health and medicine. New York: Oxford University Press, 1996
6. Coplan PM, Noel RA, Levitan BS, et al. Development of a framework for enhancing the transparency, reproducibility and communication of the benefit-risk balance of medicines. Clin Pharmacol Ther 2011; 89: 312-25
7. Levitan B, Andrews E, Gilsenan A, et al. Application of the BRAT framework to case studies: observations and insights. Clin Pharmacol Ther 2011; 89: 217-24
8. Phillips LD, Fasolo B, Zafiropolous N, et al. Is quantitative benefit-risk modeling of drugs desirable or possible? Drug Discov Today Technol 2011; 8: e3-10
9. Temple R. Quantitative decision analysis: a work in progress. Clin Pharmacol Ther 2007; 82 (2): 127-30
10. Fischhoff B, Kadvany J. Risk: a very short introduction. Oxford: Oxford University Press, 2011
11. Kahneman D. Thinking, fast and slow. New York: Farrar, Straus & Giroux, 2011
12. Dawes RM. The robust beauty of improper linear models in decision making. Am Psychol 1979; 34: 571-82
13. Meehl PE. Clinical versus statistical prediction. Minneapolis (MN): University of Minnesota Press, 1954
14. Gawande A. No mistake. The New Yorker 1998 Mar 30; 74-81
15. Gawande A. The checklist manifesto. New York: Henry Holt, 2009
16. Fischhoff B, Brewer N, Downs JS, editors. Communicating risks and benefits: an evidence-based user's guide. Washington, DC: US FDA, 2011
17. Hastie R, Dawes RM. Rational choice in an uncertain world. 2nd ed. Thousand Oaks (CA): Sage, 2010
18. Tversky A, Kahneman D. Judgment under uncertainty: heuristics and biases. Science 1974; 185: 1124-31
19. Edwards W, Lindman HR, Savage LJ. Bayesian statistical inference for psychological research. Psychol Rev 1963; 70: 193-242
20. Fischhoff B, Beyth-Marom R. Hypothesis evaluation from a Bayesian perspective. Psychol Rev 1983; 90: 239-60
21. Phillips LD. Bayesian statistics for the social sciences. London: Thomas Nelson, 1974
22. Hunink M, Glasziou P, Siegel JE, et al. Decision making in health and medicine: integrating evidence and values. Cambridge: Cambridge University Press, 2011
23. O'Hagan A, Buck CE, Daneshkhah A, et al. Uncertain judgements: eliciting expert probabilities. Chichester:Wiley, 2006
24. Fischhoff B. What forecasts (seem to) mean. Int J Forecast 1994; 10: 387-403
25. Campbell P. Understanding the receivers and the reception of science's uncertain messages. Philos Trans Royal Soc 2011; 369: 4891-912
26. Murphy AH, Lichtenstein S, Fischhoff B, et al. Misinterpretations of precipitation probability forecasts. Bull Am Meteorolog Soc 1980; 61: 695-701
27. Schwarz N. Self reports. Am Psychol 1999; 54: 93-105
28. Budescu DV, Broomell S, Por H-H. Improving communication of uncertainty in reports of the IPCC. Psycholog Sci 2009; 20: 299-308
29. Downs JS. Evaluation. In: Fischhoff B, Brewer N, Downs JS, editors. Communicating risks and benefits: an evidencebased user's guide. Washington, DC: US FDA, 2011: 11-8
30. Schwartz A, Bergus G. Medical decision making. New York: Cambridge University Press, 2008
31. SoxHC, BlattMA,HigginsMC, et al.Medical decision making. Philadelphia (PA): American College of Physicians, 2007
32. Turner CF, Martin E, editors. Surveying subjective phenomena. Washington, DC: National Academy Press, 1984
33. Crouch EAC, Wilson R. Risk-benefit analysis. Cambridge (MA): Harvard University Press, 1981
34. Kunda Z. The case for motivated cognition. Psychol Bull 1990; 108: 480-98
35. Turner RM, Spiegelhalter DJ, Smith G, et al. Bias modelling in evidence synthesis. J R Stat Soc Series A 2009; 172 (1): 21-47
36. Fischhoff B, Manski C, editors. The elicitation of preferences. Boston (MA): Kluwer, 1999
37. Lichtenstein S, Slovic P, editors. Construction of preferences. New York: Cambridge University Press, 2006
38. Fischhoff B. Cognitive processes in stated preference methods. In: Maler K-G, Vincent J, editors. Handbook of environmental economics. Amsterdam: Elsevier, 2005: 937-68
39. Bruine de Bruin W, Fischhoff B, Brilliant L, et al. Expert judgments of pandemic influenza. Glob Public Health 2006; 1 (2): 178-93
40. Lofstedt RE. Risk management in post-trust societies. Basingstoke: Palgrave/MacMillan, 2005
41. Lofstedt R, Bouder F, Chakraborty S. Transparency and the FDA: a quantitative study. J Health Commun. In press
42. Reyna VF. A theory of medical decision making and health: fuzzy-trace theory. Med Decis Making 2008; 28: 850-65
43. FDA. Guidance for industry: medication guides-distribution requirements and inclusion in risk evaluation and mitigation strategies (REMS). Washington, DC: FDA, 2011
44. Felli JC, Noel RA, Cavazzoni PA. A multiattribute model for evaluating the benefit-risk tradeoffs of treatment alternatives. Med Decis Making 2009; 29: 104-15
45. Eggers S. FDA CDER's benefit-risk assessment framework. ISPOR International 2012 Annual Meeting; 2012 Jun 5; Washington, DC
46. Jenkins J. A United States regulator's perspective on risk benefit considerations [online]. Available from URL: www.fda.gov/downloads/aboutFDA/ CentersOffices/CDER/UCM210155.pdf [Accessed 2012 Apr 14]
47. Walker S, McAuslane JN, Liberti L. Developing a common benefit-risk assessment methodology for medicines: a progress report. Scrip Regul Aff 2011 Dec; 18-21
48. Beasley BN, Unger EF, Temple R. Anticoagulant options: why the FDA approved a higher but not lower dose of dabigatran. N Engl J Med 2011; 364: 1788-90
49. Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide: the FDA's review of a new antidiabetic therapy. N Engl J Med 2010; 362: 774-7
50. Breckenridge A. Regulatory challenges, reimbursement, and risk-benefit assessment. Clin Pharmacol Ther 2010; 88: 153-4
51. Eichler HG, Pignatti F, Flamion B, et al. Balancing early market access to new drugs with the need for benefit/risk data. Nat Rev Drug Discov 2008; 7: 818-26
52. European Medicines Agency. Benefit-risk methodology project. Brussels: European Medicines Agency, 2009
53. Mussen F, Salek S, Walker S, et al. A quantitative approach to benefit-risk assessment of medicines. Pharmacepidemiol Drug Saf 2007; 16: S2-41
54. Morgan MG, Henrion M. Uncertainty. New York: Cambridge University Press, 1990
55. Funtowicz SO, Ravetz JR. Uncertainty and quality in science for policy. Dordrecht: Kluwer, 1990
56. NUSAP.net: robust knowledge for sustainability [online]. Available from URL: http://www.nusap.net [Accessed 2012 Sep 7]
57. National Research Council. Intelligence analysis for the future. Washington, DC: National Academy Press, 2011
58. Fischhoff B. Communicating uncertainty: fulfilling the duty to inform. Issues Sci Technol 2012; 29: 63-70